Search

Your search keyword '"Bandmann, O"' showing total 313 results

Search Constraints

Start Over You searched for: Author "Bandmann, O" Remove constraint Author: "Bandmann, O"
313 results on '"Bandmann, O"'

Search Results

3. Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency.

4. A double-blind, randomized, placebo-controlled trial of UDCA in Parkinson’s disease

12. Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study

16. Identification of symbol digit modality test score extremes in Huntington's disease

17. TIGAR inclusion pathology is specific for Lewy body diseases

20. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group

24. The effect of hyperglycemia on neurovascular coupling and cerebrovascular patterning in zebrafish

25. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with either Sporadic or Familial Alzheimer's Disease

26. Parkinson's disease in Sub-Saharan Africa: A review of epidemiology, genetics and access to care

32. Suicidal ideation in a European Huntington's disease population

33. Inhibition of the mitochondrial calcium uniporter (MCU) rescues dopaminergic neurons in pink1-/- zebrafish

34. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death

35. The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients

36. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY

37. NMDA receptor gene variations as modifiers in Huntington disease: a replication study

38. Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY

39. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease

41. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration

42. Discrepancies in reporting the CAG repeat lengths for Huntington's disease

44. NMDA receptor gene variations as modifiers in Huntington disease

45. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss

47. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.

49. C9ORF72 expansions, parkinsonism, and Parkinson disease: A clinicopathologic study

Catalog

Books, media, physical & digital resources